152 related articles for article (PubMed ID: 34840655)
1. Evaluating the Effect of Incobotulinumtoxin A for Glabellar, Forehead, and Crow's Feet Lines Using A High Dilution.
Barbarino SC; van Loghem JAJ; Burgess CM; Corduff N
J Clin Aesthet Dermatol; 2021 Aug; 14(8):34-40. PubMed ID: 34840655
[TBL] [Abstract][Full Text] [Related]
2. Evaluating an incobotulinumtoxinA and Cohesive Polydensified Matrix
Barbarino SC; Woodward JA; Levine J; Fezza J
J Cosmet Dermatol; 2021 May; 20(5):1459-1466. PubMed ID: 33051971
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Lateral Periorbital Lines with Different Dilutions of IncobotulinumtoxinA.
Muti GF; Basso M
J Clin Aesthet Dermatol; 2017 Sep; 10(9):27-29. PubMed ID: 29344324
[No Abstract] [Full Text] [Related]
4. Assessment of the Efficacy and Durability of IncobotulinumtoxinA in the Treatment of the Upper Face in Adult Women.
de Almeida AT; de Sanctis Pecora C; Marques ER; Contin L; de Almeida CT; da Cunha AL
Dermatol Ther (Heidelb); 2024 Jul; ():. PubMed ID: 38954382
[TBL] [Abstract][Full Text] [Related]
5. Safety, Tolerability, and Efficacy of Repeat-Dose Injections of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results from a Prospective, Open-Label, Phase III Study.
Fischer T; Sattler G; Prager W; Rzany B; Pavicic T; Gauglitz G; Weissenberger P; Riaz S
J Drugs Dermatol; 2020 May; 19(5):461-469. PubMed ID: 32484631
[TBL] [Abstract][Full Text] [Related]
6. IncobotulinumtoxinA Is an Effective and Well-Tolerated Treatment for Upper Facial Lines: Results From an Open-Label Extension Period of a Phase III Study.
Trevidic P; Connolly SA; Biwer B; Ellers-Lenz B; Harrington LS; Kestemont P; Noah EM; Sattler G; Weissenberger P; Kerscher M
Dermatol Surg; 2017 Dec; 43 Suppl 3():S285-S292. PubMed ID: 33065954
[TBL] [Abstract][Full Text] [Related]
7. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
Carruthers A; Carruthers J; Coleman WP; Donofrio L; Flynn T; Gold M; Heinz M; Harrington L; Jones D; McDaniel D; Rohrer T; Schlöbe A; Solish N; Weiss RA
Dermatol Surg; 2013 Apr; 39(4):551-8. PubMed ID: 23379292
[TBL] [Abstract][Full Text] [Related]
8. IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines.
Kerscher M; Fabi S; Fischer T; Gold M; Joseph J; Prager W; Rzany B; Yoelin S; Roll S; Klein G; Maas C
J Drugs Dermatol; 2020 Oct; 19(10):985-991. PubMed ID: 33026771
[TBL] [Abstract][Full Text] [Related]
9. Remodeling of periorbital, temporal, glabellar, and crow's feet areas with hyaluronic acid and botulinum toxin.
Beer KR; Julius H; Dunn M; Wilson F
J Cosmet Dermatol; 2014 Jun; 13(2):143-50. PubMed ID: 24910278
[TBL] [Abstract][Full Text] [Related]
10. A Prospective, Neurophysiologic Comparative Study to Assess the Efficacy and Duration of Effect of IncobotulinumtoxinA and AbobotulinumtoxinA in the Treatment of Crow's Feet.
Saybel A; Artemenko A; Nikitin S; Kurenkov A
J Drugs Dermatol; 2015 Nov; 14(11):1291-6. PubMed ID: 26580879
[TBL] [Abstract][Full Text] [Related]
11. Aesthetic ONE21 Technique for Injecting IncobotulinumtoxinA into the Forehead: Initial Experience With 86 Patients.
de Sanctis Pecora C; Bussamara Pinheiro MV; Figueiredo V; Guerra R
J Drugs Dermatol; 2021 Jan; 20(1):31-37. PubMed ID: 33400422
[TBL] [Abstract][Full Text] [Related]
12. Different injection patterns of incobotulinumtoxinA for crow's feet: a split-face comparative study.
Vachiramon V; Subpayasarn U; Triyangkulsri K; Jurairattanaporn N; Rattananukrom T
J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):256-262. PubMed ID: 33068445
[TBL] [Abstract][Full Text] [Related]
13. IncobotulinumtoxinA use in aesthetic indications in daily practice: a European multicenter, noninterventional, retrospective study.
Pavicic T; Prager W; Klöppel M; Ravichandran S; Galatoire O
Clin Cosmet Investig Dermatol; 2015; 8():135-42. PubMed ID: 25834463
[TBL] [Abstract][Full Text] [Related]
14. Subject satisfaction and psychological well-being with escalating abobotulinumtoxinA injection dose for the treatment of moderate to severe glabellar lines.
Dayan S; Joseph J; Moradi A; Lorenc ZP; Coleman K; Ablon G; Kaufman-Janette J; Cox SE; Campbell A; Munavalli G; Prygova I
J Cosmet Dermatol; 2022 Jun; 21(6):2407-2416. PubMed ID: 35266281
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of IncobotulinumtoxinA for the treatment of platysmal bands of the aging neck: an open-label, prospective pilot study.
Gubanova EI; Panova OS; Sanchez EA; Rodina MY; Starovatova PA
J Drugs Dermatol; 2013 Dec; 12(12):1461-6. PubMed ID: 24301249
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines.
Lim JTE; Loh DK; Soh K; Sunga O
Singapore Med J; 2017 Oct; 58(10):606-609. PubMed ID: 27357317
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the Use of IncobotulinumtoxinA in Combination with Calcium Hydroxylapatite with Integral Lidocaine for Improving Chin Profile Projection Aesthetics.
Barbarino SC; Day D; Rivkin A; Levine J; Fezza J
J Clin Aesthet Dermatol; 2024 Feb; 17(2):24-28. PubMed ID: 38444424
[TBL] [Abstract][Full Text] [Related]
18. IncobotulinumtoxinA for the Treatment of Glabellar Frown Lines: A Prospective, Multicenter, Single-arm Study in Taiwan.
Chao YY; Tseng FW; Yang YL; Chen YH; Hsu NJ; Chang LY
J Clin Aesthet Dermatol; 2019 Dec; 12(12):E53-E57. PubMed ID: 32038766
[No Abstract] [Full Text] [Related]
19. Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From a Randomized, Double-Blind, Placebo-Controlled, Phase III Study.
Kerscher M; Rzany B; Prager W; Turnbull C; Trevidic P; Inglefield C
Dermatol Surg; 2015 Oct; 41(10):1149-57. PubMed ID: 26359996
[TBL] [Abstract][Full Text] [Related]
20. SAMCEP Society consensus on the treatment of upper facial lines with botulinum neurotoxin type A: A tailored approach.
Braccini F; Catoni I; Belfkira F; Lagier J; Roze E; Paris J; Huth J; Bronsard V; Cartier H; David M; Galatoire O; Obadia D; Sabatier H; Sarfati E; Kestemont P; Winter C; Redaelli A
J Cosmet Dermatol; 2023 Oct; 22(10):2692-2704. PubMed ID: 37408173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
